𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose dexamethasone in refractory B-cell chronic lymphocytic leukemia patients

✍ Scribed by Stefano Molica

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
124 KB
Volume
47
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Thalidomide and dexamethasone therapy of
Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia
✍ James C. Barton πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 68 KB πŸ‘ 2 views

## Abstract A 67‐year‐old woman with previously untreated lambda‐positive B‐chronic lymphocytic leukemia (CLL) had kappa‐positive myeloma develop that was treated with daily thalidomide and intermittent dexamethasone. After 4 months, there was a marked reduction in marrow plasmacytosis, urine kappa

Modulation of apoptosis by cytokines in
Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia
✍ R. CastejΓ³n; J.A. Vargas; Y. Romero; M. Briz; R.M. MuΓ±oz; A. DurΓ‘ntez πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 268 KB πŸ‘ 2 views

B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the slow and progressive accumulation of monoclonal apparently mature, CD5 Ψ‰ B lymphocytes. The majority of circulating cells appear to be nondividing, and it has been suggested that a prolonged life span is mainly responsible for the a

High-dose liposomal daunorubicin and hig
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
✍ Jorge Cortes; Elihu Estey; Susan O'Brien; Francis Giles; Yu Shen; Charles Koller πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 2 views

## Background: Liposomal encapsulation of daunorubicin (daunoxome, dnx; nexstar pharmaceutical, boulder, co) changes the pharmacology profile to increase delivery to tumor sites and decrease toxicity. the authors investigated the effect of daunorubicin in combination with ara-c in patients with ref